ArticleApplied biochemistry and biotechnology2026
DDX11/SKP2 Inhibits Cisplatin Sensitivity in Liver Cancer Cells by Regulating DNA Damage Repair and ER Stress.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cisplatin is mainly used for treating terminal hepatocellular carcinoma (HCC), but the development of drug resistance limits its clinical efficacy in treating this disease. The helicase activity of DDX11 can prevent hypersensitivity to chemotherapy drugs and DNA damage. The aim of this study was to explore the potential molecular mechanism through which DDX11 mediates cisplatin resistance in HCC. HepG2 and Huh7 cisplatin-resistant strains were established and named HepG2-DDP and Huh7-DDP, respectively. Cell proliferation and DNA damage were measured by CCK-8, colony formation and comet assays, and the expression of related proteins and genes was detected by Western blotting, immunohistochemistry, immunofluorescence and RT‒qPCR. The HepG2-DDP and Huh7-DDP cell lines were xenografted subcutaneously into nude mice to investigate the role of DDX11 in vivo. DDX11 expression was upregulated in HCC clinical samples and cell lines. DDX11 knockdown inhibited HCC cell proliferation and promoted sensitivity to cisplatin, DNA damage and endoplasmic reticulum (ER) stress, and SKP2 knockdown weakened the effects of DDX11 overexpression and promoted cisplatin-induced ER stress. Mechanistically, DDX11 inhibited cisplatin-induced DNA damage and ER stress by upregulating SKP2 expression, ultimately reducing the sensitivity of HCC cells to cisplatin. This study revealed that the DDX11/SKP2 axis may be a promising therapeutic target for improving resistance to cisplatin in patients with HCC.
Indexed as
Identifiers
41489706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.